Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA-mutated Solid Tumor”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Early research (Phase 1)Study completedNCT01339650
What this trial is testing

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian TubePrimary Peritoneal CancerSolid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian
AbbVie (prior sponsor, Abbott) 93
Testing effectiveness (Phase 2)Study completedNCT01078662
What this trial is testing

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Who this might be right for
OvarianBreastProstate+2 more
AstraZeneca 298
Early research (Phase 1)Not Yet RecruitingNCT07088588
What this trial is testing

Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid CancerMetastatic Solid TumorOvarian Cancer+3 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd 105
Early research (Phase 1)Study completedNCT04672460
What this trial is testing

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsSolid TumorsOvarian Cancer+5 more
Pfizer 73
Testing effectiveness (Phase 2)Looking for participantsNCT06395519
What this trial is testing

PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Who this might be right for
Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+10 more
858 Therapeutics, Inc. 120
Early research (Phase 1)Not Yet RecruitingNCT06614751
What this trial is testing

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Who this might be right for
Solid CancersBRCA MutationHRD Cancer+8 more
Danatlas Pharmaceuticals Co., Ltd 112
Early research (Phase 1)UnknownNCT03415659
What this trial is testing

Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsHRDBRCA Mutation
Hubei Biological Medicine Industrial Technology Institute Co., Ltd. 85
Early research (Phase 1)Study completedNCT00526617
What this trial is testing

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Who this might be right for
Non-hematologic MalignanciesMetastatic MelanomaBreast Cancer+4 more
AbbVie 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT06380660
What this trial is testing

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultBRCA1 MutationBRCA2 Mutation+3 more
Acerand Therapeutics (Shanghai) Limited 298
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Testing effectiveness (Phase 2)Ended earlyNCT06065059
What this trial is testing

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Who this might be right for
Breast CancerOvarian CancerPancreas Cancer+5 more
Tango Therapeutics, Inc. 7
Early research (Phase 1)Ended earlyNCT02358200
What this trial is testing

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Who this might be right for
Triple Negative Metastatic Breast CancerBRCA-mutated Solid Tumor
Pamela Munster 23
Testing effectiveness (Phase 2)Study completedNCT01482715
What this trial is testing

Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer+1 more
pharmaand GmbH 136
Early research (Phase 1)Study completedNCT01853306
What this trial is testing

Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Who this might be right for
OncologyBRCA MutatedHigh Grade Serous Ovarian Cancer+1 more
AbbVie 71
Early research (Phase 1)Study completedNCT00892736
What this trial is testing

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Who this might be right for
Basal-Like Breast CarcinomaBRCA1 Mutation CarrierBRCA2 Mutation Carrier+14 more
National Cancer Institute (NCI) 98
Early research (Phase 1)Looking for participantsNCT06666270
What this trial is testing

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid CancerMetastatic Solid TumorOvarian Cancer+4 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd 30
Early research (Phase 1)UnknownNCT02950064
What this trial is testing

Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

Who this might be right for
Pancreatic NeoplasmsOvarian NeoplasmsBreast Neoplasms+1 more
Placon Therapeutics 95
Early research (Phase 1)Active Not RecruitingNCT04673448
What this trial is testing

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8BRCA-Associated Malignant Neoplasm+24 more
University of Washington 18